World's Best Scientists 2026 revealed!
Dionyssios Katsaros

Dionyssios Katsaros

D-Index & Metrics

Medicine

D-Index
89
Citations
29683
World Ranking
12677
National Ranking
483

Overview

Dionyssios Katsaros is affiliated with the University of Turin in Italy. Their research primarily focuses on the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with particular attention to subfields such as Reproductive Medicine, Oncology, Cancer Research, Obstetrics and Gynecology, and Pulmonary and Respiratory Medicine.

The scientist's research encompasses several main topics, including:

  • Ovarian cancer diagnosis and treatment
  • Endometrial and Cervical Cancer Treatments
  • Cancer-related molecular mechanisms research
  • Cancer Genomics and Diagnostics
  • PARP inhibition in cancer therapy
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Research Studies

Recent publications authored or co-authored by Katsaros include:

  • Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial, 2023, The Lancet
  • Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup, 2022, The Lancet Oncology
  • Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives, 2020, Diagnostics
  • Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994, 2023, Journal of Clinical Oncology
  • The "scar" of a pandemic: Cumulative incidence of COVID-19 during the first trimester of pregnancy, 2020, Journal of Medical Virology

Katsaros frequently collaborates with several co-authors, including:

  • Fulvio Borella
  • Stephanie M. de Boer
  • Remi A. Nout
  • Linda Mileshkin
  • Hans W. Nijman

Their work has appeared in various publication venues, notably:

  • International Journal of Gynecological Cancer
  • Radiotherapy and Oncology
  • Zenodo (CERN European Organization for Nuclear Research)
  • The Lancet Oncology
  • Journal of Clinical Oncology

Best Publications

  • Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

    Lin Zhang;Jose R. Conejo-Garcia;Dionyssios Katsaros;Phyllis A. Gimotty

  • Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial

    Pierluigi Benedetti Panici;Stefano Basile;Francesco Maneschi;Andrea Alberto Lissoni

  • microRNAs exhibit high frequency genomic alterations in human cancer

    Lin Zhang;Jia Huang;Nuo Yang;Joel Greshock

  • The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis

    Huang Q;Gumireddy K;Schrier M;le Sage C

  • Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer

    Lin Zhang;Stefano Volinia;Tomas Bonome;George Adrian Calin

  • Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers

    Xiaohui Yan;Xiaohui Yan;Zhongyi Hu;Yi Feng;Xiaowen Hu

  • Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A.

    Jose R. Conejo-Garcia;Fabian Benencia;Maria Cecilia Courreges;Eugene Kang

  • Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

    Stephanie M. de Boer;Melanie E. Powell;Linda Mileshkin;Dionyssios Katsaros

  • MicroRNA Microarray Identifies Let-7i as a Novel Biomarker and Therapeutic Target in Human Epithelial Ovarian Cancer

    Nuo Yang;Sippy Kaur;Stefano Volinia;Joel Greshock

  • Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

    Stephanie M de Boer;Melanie E Powell;Linda Mileshkin;Dionyssios Katsaros

  • miR-210 Links Hypoxia with Cell Cycle Regulation and Is Deleted in Human Epithelial Ovarian Cancer

    Antonis Giannakakis;Raphael Sandaltzopoulos;Joel Greshock;Shun Liang

  • A Functional Genomic Approach Identifies FAL1 as an Oncogenic Long Noncoding RNA that Associates with BMI1 and Represses p21 Expression in Cancer

    Xiaowen Hu;Yi Feng;Dongmei Zhang;Dongmei Zhang;Sihai D. Zhao

  • Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.

    Sandro Pignata;Giovanni Scambia;Dionyssios Katsaros;Ciro Gallo

  • High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1

    Biyun Qian;Dionyssios Katsaros;Lingeng Lu;Mario Preti

  • Tumor-derived Vascular Endothelial Growth Factor Up-Regulates Angiopoietin-2 in Host Endothelium and Destabilizes Host Vasculature, Supporting Angiogenesis in Ovarian Cancer

    Lin Zhang;Nuo Yang;Jin-Wan Park;Dionyssios Katsaros

  • Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer

    Gabriella Ferrandina;Manuela Ludovisi;Domenica Lorusso;Sandro Pignata

  • Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis.

    Lingeng Lu;Dionyssios Katsaros;Irene A. Rigault de la Longrais;Olga Sochirca

  • Overexpression of the MET/HGF receptor in ovarian cancer

    M. F. Di Renzo;M. Olivero;D. Katsaros;T. Crepaldi

  • Human Kallikrein 6 (hK6): A New Potential Serum Biomarker for Diagnosis and Prognosis of Ovarian Carcinoma

    Eleftherios P Diamandis;Andreas Scorilas;Stefano Fracchioli;Marleen Van Gramberen

  • Randomized Trial of Neoadjuvant Chemotherapy Comparing Paclitaxel, Ifosfamide, and Cisplatin With Ifosfamide and Cisplatin Followed by Radical Surgery in Patients With Locally Advanced Squamous Cell Cervical Carcinoma: The SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study

    Alessandro Buda;Roldano Fossati;Nicoletta Colombo;Francesca Fei

Frequent Co-Authors

Eleftherios P. Diamandis
Eleftherios P. Diamandis Mount Sinai Hospital
Lingeng Lu
Lingeng Lu Yale University
Lin Zhang
Lin Zhang University of Pennsylvania
Andreas Scorilas
Andreas Scorilas National and Kapodistrian University of Athens
George Coukos
George Coukos Cornell University
George M. Yousef
George M. Yousef University of Toronto
Giovanni Scambia
Giovanni Scambia Catholic University of the Sacred Heart
Harvey A. Risch
Harvey A. Risch Yale University
Sandro Pignata
Sandro Pignata National Cancer Institute
Sergio Pecorelli
Sergio Pecorelli University of Brescia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine opens up several related opportunities in healthcare. For students interested in nursing, there are direct entry msn programs for non nurses online that offer an accelerated path to an advanced nursing degree, even for those without prior nursing experience.

If you're looking for accessible options, some direct admit nursing programs make entering the field easier by streamlining admissions. Additionally, not all nursing programs require entrance exams; explore do all nursing schools require the teas for options that don't require the TEAS or HESI.

For those interested in healthcare administration, medical coding and billing classes online with financial aid are also available. These programs can provide flexible and affordable pathways into the healthcare industry without patient care duties.

Whether your interest lies in direct patient care or behind-the-scenes roles, there are many online degrees and career pathways in healthcare to fit your goals.

Best Scientists Citing Dionyssios Katsaros

Trending Scientists